Euro vs US Dollar

Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

Registrieren

ALNY Alnylam Pharmaceuticals Inc

151,37

-0,92 (-0,60%)

10 Mai 2024 - Geschlossen

Verzögert um 15 Minuten

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Article too big to display. Click here to view on the SEC website

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
Von Apr 2024 bis Mai 2024

Click Here for more Alnylam Pharmaceuticals Charts.

Alnylam Pharmaceuticals (NASDAQ:ALNY)
Historical Stock Chart
Von Mai 2023 bis Mai 2024

Click Here for more Alnylam Pharmaceuticals Charts.

News Alnylam Pharmaceuticals Inc

Alnylam Issues 2023 Corporate Responsibility Report
Dienstag 7 Mai 2024 (3 Tage vor) • Business Wire

Alnylam Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Period Activity
Donnerstag 2 Mai 2024 (1 Woche vor) • Business Wire

Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in Europe and Israel to Commercialize RNAi Therapeutics in additional LATAM and APAC markets including Australia
Dienstag 30 April 2024 (1 Woche vor) • PR Newswire (US)

Alnylam to Webcast Conference Call Discussing First Quarter 2024 Financial Results
Donnerstag 18 April 2024 (3 Wochen vor) • Business Wire

Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension
Sonntag 7 April 2024 (1 Monat vor) • Business Wire

Alnylam to Webcast Investor Event to Discuss Results from KARDIA-2 Phase 2 Study of Zilebesiran at American College of Cardiology Scientific Session
Mittwoch 20 März 2024 (2 Monate vor) • Business Wire

Alnylam Launches Hereditary ATTR (hATTR) Amyloidosis Campaign to Help Shorten Time to Diagnosis for Inherited and Rapidly Progressive Disease
Mittwoch 13 März 2024 (2 Monate vor) • Business Wire

Alnylam meldet positive KARDIA-2 Topline-Studienergebnisse, die eine klinisch signifikante Blutdrucksenkung bei Zugabe von Zilebesiran zu Standard-Blutdrucksenkern belegen
Mittwoch 6 März 2024 (2 Monate vor) • Business Wire

Alnylam annonce des résultats positifs de l’étude KARDIA-2 démontrant des réductions cliniquement significatives de la pression artérielle lorsque le zilebesiran est ajouté à des antihypertenseurs standards
Dienstag 5 März 2024 (2 Monate vor) • Business Wire

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities
Dienstag 5 März 2024 (2 Monate vor) • Edgar (US Regulatory)

Weitere Alnylam Pharmaceuticals Inc News-Artikel

Deutsche Telekom

Energy Select Sector SPDR

Gold vs US Dollar

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen